

Telomere length is a critical determinant for survival in multiple myeloma

3

4 Sam Hyatt,^{1*} Rhiannon E. Jones,^{1*} Nicole H. Heppel,¹ Julia W. Grimstead,¹ Chris
5 Fegan,¹ Graham H. Jackson², Robert Hills,¹ James M. Allan,³ Guy Pratt,⁴ Chris
6 Pepper¹⁺ and Duncan M. Baird.¹⁺

7

8 *Equal contributions

9 +Joint senior authors

10

11 ¹Division of Cancer & Genetics, School of Medicine, Cardiff University, Heath Park,
12 Cardiff, CF14 4XN, UK. ²Department of Haematology, Royal Victoria Infirmary,
13 Newcastle upon Tyne, UK. ³Northern Institute for Cancer Research, Newcastle
14 University, Newcastle-upon-Tyne, UK. ⁴Centre for Clinical Haematology, University
15 Hospitals Birmingham NHS Foundation Trust, Birmingham.

16 **Running title:** Telomere based prognostication in Multiple Myeloma

17 **Keywords:** Multiple Myeloma, prognosis, telomere, genome instability

18

1 **Summary**

2 Patients with Multiple Myeloma (MM) exhibit variable clinical outcomes, which are
3 incompletely defined by the current prognostication tools. We examined the clinical
4 utility of high-resolution telomere length analysis as a prognostic marker in MM.
5 Stratification of the cohort using a previously determined length threshold for
6 telomere dysfunction revealed that patients with short telomeres had a significant
7 shorter overall survival ($P<0.0001$; $HR=3.4$). Multivariate modelling using forward
8 selection revealed that the most important prognostic factor was ISS, followed by
9 age and telomere length. Importantly, each ISS prognostic subset could be further
10 risk-stratified according to telomere length, supporting the inclusion of this
11 parameter as a refinement of the ISS.

1 Despite the introduction of novel therapeutic modalities, patients with multiple
2 myeloma (MM) display a heterogeneous clinical course, with survival ranging from a
3 few months to over 10 years. Therefore, there is a requirement for reliable
4 prognostic and predictive markers in this disease to allow for risk stratification and
5 rational clinical decision-making. The most commonly used prognostic system in MM
6 is the International Staging System (ISS) that is based on serum levels of both β_2 -
7 micoglobulin and albumin (Greipp, *et al* 2005). Recently the ISS system has been
8 improved upon by the inclusion of cytogenetic information to take into account the
9 considerable genetic heterogeneity known to occur in this disease and the level of
10 lactate dehydrogenase (Palumbo, *et al* 2015). Hyperdiploidy and the loss of whole
11 chromosome arms is frequently detected in MM, this includes, amongst others,
12 gains of 1q in 30% of cases and the loss of 17p in 7% of cases (Walker, *et al* 2010).

13

14 Short dysfunctional telomeres are susceptible to DNA repair activities that can result
15 in chromosomal fusion and the initiation of cycles of anaphase-bridging, breakage
16 and fusion that can drive genomic instability and clonal evolution (Artandi, *et al*
17 2000, Jones, *et al* 2014, Roger, *et al* 2013). Telomere dysfunction has been
18 documented in numerous haematological malignancies (Jones, *et al* 2012), this is
19 one putative mechanism that may lead to the genetic and clinical heterogeneity
20 observed in MM (Wu, *et al* 2003) and may relate to changes in the 3D telomeric
21 architecture that have been documented in MM cells (Klewes, *et al* 2013). Recently
22 we have shown that high-resolution telomere analysis, combined with a functional
23 definition of telomere length, can provide powerful prognostic information in several
24 tumour types, including chronic lymphocytic leukaemia (CLL)(Lin, *et al* 2014),

1 myelodysplasia (Williams et al. in prep) and breast cancer (Simpson, *et al* 2015).
2 Here we sought to apply these technologies to examine the prognostic utility of
3 telomere length in MM.

4

5 Materials and Methods

6 Patients samples and cell separation

7 Patient samples were collected at diagnosis, prior to treatment, through treating
8 centres within the Heart of England NHS Foundation Trust and the Newcastle upon
9 Tyne NHS Foundation Trust between 1990 and 2005, with ethical approval from the
10 Newcastle Haematology Biobank (07/H0906/109+5) in accordance with the
11 declaration of Helsinki. Bone marrow samples from five MM patients were
12 fractionated into CD138⁺ and CD138⁻ cells using positive selection with CD138+
13 microbeads and the AutoMACS system (Miltenyi). Cytogenetics was not available on
14 these samples and thus the original ISS staging system was used for this study
15 (Greipp, *et al* 2005).

16 DNA extraction and single telomere length analysis

17 DNA was extracted from sorted cell populations using the Qiagen DNeasy blood and
18 tissue extraction kit, according to the manufacturers instructions. Single telomere
19 length analysis (STELA) at the XpYp telomere was performed as previously described
20 (Baird, *et al* 2003, Britt-Compton, *et al* 2006, Capper, *et al* 2007). A minimum of 6
21 PCR reactions per sample were carried out for each test DNA and DNA fragments
22 were resolved by agarose gel electrophoresis, and detected by Southern
23 hybridisations and phosphorimaging.

24 Statistical methods

1 Statistical analysis was carried out using Prism 6.0 (Graphpad) and SAS version 9.3
2 software (SAS Institute). Univariate comparisons for overall survival (OS) were
3 conducted with the log-rank test and displayed as Kaplan Meier curves. $P < .05$ was
4 considered significant. Analyses of time to event outcomes with respect to
5 continuous variables or those with less than two categories, together with
6 multivariable analyses, were performed using a Cox proportional hazard model with
7 forward selection. $P < 0.05$ was considered significant.

8

9 **Results and discussion**

10

11 We used Single Telomere Length Analysis (STELA) of the XpYp telomere to generate
12 telomere length profiles from unsorted bone marrow samples derived from a cohort
13 of 61 patients with MGUS and 134 patients with MM (Figure 1A). STELA is a high-
14 resolution technology capable of detecting telomeres within the length ranges at
15 which telomere fusion is known to occur (Letsolo, *et al* 2010, Lin, *et al* 2014). STELA
16 also provides information on telomere length distributions, which relate to the
17 clonality, replicative history and the cell purity of the tumour cell population
18 analysed. At the individual patient level, it was apparent that the telomeres in both
19 the MGUS and MM bone marrow samples displayed considerable length
20 heterogeneity (Figure 1A), with an overall mean of the SDs obtained from these
21 distributions in the MGUS cohort of 2.23 kb and 2.12 kb for the MM cohort. This was
22 in contrast to a similar analysis in CLL (Lin, *et al* 2010) where purified tumour cells
23 were analysed and individual telomere length distributions were significantly more
24 homogeneous (mean SD = 1.28) compared to those observed in MM and MGUS
25 patients ($p < .0001$; Mann-Whitney). The telomere length heterogeneity in the MM

1 samples was consistent with the differing replicative histories of the numerous cell
2 populations that composed the unsorted bone marrow samples analysed.

3

4 The majority of telomere length profiles derived from MM patient samples displayed
5 multi-modal distributions with sub-populations of cells displaying more extensive
6 telomere erosion (highlighted in red in Figure 1A). To examine the telomere length
7 distributions of purified myeloma plasma cell populations, we undertook cell sorting
8 in a subset of myeloma bone marrow samples ($n = 5$) and analysed the CD138⁺ and
9 CD138⁻ cell fractions separately. Distinct differences in the telomere length
10 distributions were apparent (Figure 1B), with CD138⁺ plasma cells (mean = 2.40kb)
11 displaying significant telomere erosion compared to the CD138⁻ cells (mean = 5.26kb;
12 $p = .008$). These data indicate that the shorter telomere length distribution observed
13 in unsorted MM samples represent CD138⁺ malignant plasma cells. Importantly
14 these data are consistent with MM plasma cells exhibiting an extensive replicative
15 history that is distinct to that of bone marrow CD138⁻ cells in these patients.

16

17 Overall, telomere length was shorter in MM compared to MGUS patient samples ($P =$
18 $.017$; Mann-Whitney) with 19% of MM samples within the fusogenic range (Figure
19 1C); the telomere length threshold below which we detected telomere fusions in CLL
20 (3.81kb)(Lin, *et al* 2014). Telomere length declined as a function of age in MM at
21 rates consistent with the extensive literature on telomere dynamics in normal
22 peripheral blood samples (-25 bp/year, $p = .00056$; Figure 1D)(Muezzinler, *et al*
23 2013). However, there was no significant difference in telomere length between any
24 of the International Staging System (ISS) subgroups ($p = .27$; Figure 1C) or between

1 sexes ($p = .22$).

2

3 The median telomere length of the MM cohort provided modest prognostic
4 resolution (HR = 1.61 (1.04-2.53), $p = .03$; data not shown). In contrast, use of the
5 previously determined telomere dysfunction threshold (Lin, *et al* 2014) was highly
6 prognostic for overall survival in MM (HR = 3.42 (3.67-15.81), $P < .0001$; Figure 2A); a
7 striking observation, given the variable contributions of plasma cells to the unsorted
8 heterogeneous samples analysed.

9

10 Consistent with previous reports, the ISS provided strong prognostic information in
11 our MM cohort (HR = 3.56 (2.92-9.13), $p < .0001$; Figure 2B), that was similar to that
12 derived using the telomere dysfunction threshold. In order to assess whether
13 telomere length could add prognostic resolution to the ISS, we performed
14 multivariate analysis on 113/131 (86.3%) MM samples on which we had all relevant
15 clinical data. In a model which included the potential covariates of mean telomere
16 length, gender, age, ISS sub-groups and the telomere dysfunction threshold (3.81kb),
17 the most important prognostic factor was ISS, followed by age and telomere length
18 below 3.81kb (Table 1). After adjustment for ISS and age, telomere length $<3.81\text{kb}$
19 was associated with significantly shorter survival (HR = 2.23 (1.26-3.96), $P = .006$;
20 Figure 2C). Despite the prognostic independence of telomere length, there was
21 evidence of an interaction between ISS and this parameter, with the effect of short
22 telomeres less prominent in patients with high risk ISS score ($P = .05$). However, in
23 univariate analyses, stratified by ISS score, short telomeres still were associated with
24 significantly worse survival in high risk ISS patients ($P = .02$). Overall, patients with

1 good or standard risk ISS who manifested short telomeres, or high risk ISS patients
2 with long telomeres had intermediate survival when compared to concordant groups
3 consisting of good/standard risk ISS and long telomeres and high risk ISS and short
4 telomeres (Figure 2D). These findings suggest that a refinement of the risk
5 classification could be obtained by incorporating telomere length assessment into
6 the ISS for MM. Given the obvious differences observed between malignant plasma
7 cells and other bone marrow constituents, we speculate that purification of the MM
8 tumour cells would further enhance the clinical utility of high-resolution telomere
9 length analysis in this disease.

1 **Acknowledgements:**

2 This work was supported by grants from Bloodwise (13033, 06002, 13044), the
3 Leukaemia Research Appeal for Wales and Cancer Research UK (C17199/A18246).

4 **Conflict of Interest Statement:**

5 SH declares no conflict of interests; REJ declares no conflict of interests; NHH
6 declares no conflict of interests; CF declares no conflict of interests other than co-
7 authorship of a patent application based on some of this work; GHJ declares no
8 conflict of interests; JMA declares no conflict of interests; GP declares no conflict of
9 interests; CP declares no conflict of interests other than co-authorship of a patent
10 application based on some of this work; DMB declares no conflict of interests other
11 than co-authorship of a patent application based on some of this work.

12

References

- Artandi, S.E., Chang, S., Lee, S.L., Alson, S., Gottlieb, G.J., Chin, L. & DePinho, R.A. (2000) Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. *Nature*, **406**, 641-645.
- Baird, D.M., Rowson, J., Wynford-Thomas, D. & Kipling, D. (2003) Extensive allelic variation and ultrashort telomeres in senescent human cells. *Nature genetics*, **33**, 203-207.
- Britt-Compton, B., Rowson, J., Locke, M., Mackenzie, I., Kipling, D. & Baird, D.M. (2006) Structural stability and chromosome-specific telomere length is governed by cis-acting determinants in humans. *Human molecular genetics*, **15**, 725-733.
- Capper, R., Britt-Compton, B., Tankimanova, M., Rowson, J., Letsolo, B., Man, S., Haughton, M. & Baird, D.M. (2007) The nature of telomere fusion and a definition of the critical telomere length in human cells. *Genes & development*, **21**, 2495-2508.
- Greipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Blade, J., Boccadoro, M., Child, J.A., Avet-Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. & Westin, J. (2005) International staging system for multiple myeloma. *J Clin Oncol*, **23**, 3412-3420.
- Jones, C.H., Pepper, C. & Baird, D.M. (2012) Telomere dysfunction and its role in haematological cancer. *Br J Haematol*, **156**, 573-587.
- Jones, R.E., Oh, S., Grimstead, J.W., Zimbric, J., Roger, L., Heppel, N.H., Ashelford, K.E., Liddiard, K., Hendrickson, E.A. & Baird, D.M. (2014) Escape from Telomere-Driven Crisis Is DNA Ligase III Dependent. *Cell Rep*, **8**, 1063-1076.
- Klewes, L., Vallente, R., Dupas, E., Brand, C., Grun, D., Guffei, A., Sathitruangsak, C., Awe, J.A., Kuzyk, A., Lichtensztejn, D., Tammur, P., Ilus, T., Tamm, A., Punab, M., Rubinger, M., Olujohungbe, A. & Mai, S. (2013) Three-dimensional Nuclear Telomere Organization in Multiple Myeloma. *Transl Oncol*, **6**, 749-756.
- Letsolo, B.T., Rowson, J. & Baird, D.M. (2010) Fusion of short telomeres in human cells is characterised by extensive deletion and microhomology and can result in complex rearrangements. *Nucleic Acids Res*, **38**, 1841-1852.
- Lin, T.T., Letsolo, B.T., Jones, R.E., Rowson, J., Pratt, G., Hewamana, S., Fegan, C., Pepper, C. & Baird, D.M. (2010) Telomere dysfunction and fusion during the progression of chronic lymphocytic leukaemia: evidence for a telomere crisis. *Blood*, **116**, 1899-1907.
- Lin, T.T., Norris, K., Heppel, N.H., Pratt, G., Allan, J.M., Allsup, D.J., Bailey, J., Cawksell, L., Hills, R., Grimstead, J.W., Jones, R.E., Britt-Compton, B., Fegan, C., Baird, D.M. & Pepper, C. (2014) Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. *Br J Haematol*, **167**, 214-223.
- Muezzinler, A., Zaineddin, A.K. & Brenner, H. (2013) A systematic review of leukocyte telomere length and age in adults. *Ageing Res Rev*, **12**, 509-519.
- Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H.M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J.J., Facon, T., Bringhen, S., Gay, F., Attal, M., Passera, R., Spencer, A., Offidani, M., Kumar, S., Musto, P., Lonial,

1 S., Petrucci, M.T., Orlowski, R.Z., Zamagni, E., Morgan, G., Dimopoulos, M.A.,
2 Durie, B.G., Anderson, K.C., Sonneveld, P., San Miguel, J., Cavo, M., Rajkumar,
3 S.V. & Moreau, P. (2015) Revised International Staging System for Multiple
4 Myeloma: A Report From International Myeloma Working Group. *J Clin*
5 *Oncol*, **33**, 2863-2869.

6 Roger, L., Jones, R.E., Heppel, N.H., Williams, G.T., Sampson, J.R. & Baird, D.M. (2013)
7 Extensive telomere erosion in the initiation of colorectal adenomas and its
8 association with chromosomal instability. *J Natl Cancer Inst*, **105**, 1202-1211.

9 Simpson, K., Jones, R.E., Grimstead, J.W., Hills, R., Pepper, C. & Baird, D.M. (2015)
10 Telomere fusion threshold identifies a poor prognostic subset of breast
11 cancer patients. *Mol Oncol*, **9**, 1186-1193.

12 Walker, B.A., Leone, P.E., Chiecchio, L., Dickens, N.J., Jenner, M.W., Boyd, K.D.,
13 Johnson, D.C., Gonzalez, D., Dagrada, G.P., Protheroe, R.K., Konn, Z.J.,
14 Stockley, D.M., Gregory, W.M., Davies, F.E., Ross, F.M. & Morgan, G.J. (2010)
15 A compendium of myeloma-associated chromosomal copy number
16 abnormalities and their prognostic value. *Blood*, **116**, e56-65.

17 Wu, K.D., Orme, L.M., Shaughnessy, J., Jr., Jacobson, J., Barlogie, B. & Moore, M.A.
18 (2003) Telomerase and telomere length in multiple myeloma: correlations
19 with disease heterogeneity, cytogenetic status, and overall survival. *Blood*,
20 **101**, 4982-4989.

21

1 **Table 1. Multivariate modelling revealed three significant independent variables.**

2

Summary of Forward Selection					
Step	Effect entered	DF	Number In	Chi-Square test statistic	p-value
1	ISS 3	1	1	34.7751	<.0001
2	age	1	2	18.1900	<.0001
3	TL <3.81kb	1	3	7.7095	0.0055

3 ISS 3: Multiple myeloma International Scoring System stage 3

4 TL <3.81kb: mean telomere length of less than 3.81kb

5 Using a Cox proportional hazards model with forward selection, only three variables
6 were deemed to hold independent prognostic significance ($p \leq .05$).

7

8

9

10


1 **Figure Legends**

2 **Figure 1. MM and MGUS exhibit heterogeneous telomere length profiles.** (A)


3 Examples of STELA of the XpYp telomere in 8 MM and MGUS samples. The mean of
4 the telomere length profiles are indicated in black below each sample. Red boxes
5 indicate the shorter modal telomere length profiles in samples that display a
6 multimodal telomere length distributions. (B) Comparison of cell sorted CD138⁺ and
7 CD138⁻ sub-populations revealed distinctly shorter telomere length profiles in
8 CD138⁺ cells. (C) Scatter plot depicting mean telomere length measurements for
9 cohorts of MGUS and MM patients, and MM ISS 1/2 and ISS 3 sub-groups. The
10 upper limit of telomere dysfunction (3.81kb) is shown as a blue horizontal line.
11 Statistical comparisons were undertaken using non-parametric Mann-Whitney
12 tests. (D) Plotting mean telomere length as a function of age shown in years. P value
13 was determined using Spearman correlation.

14 **Figure 2. Telomere length is highly prognostic in MM.** Kaplan Meier survival analysis

15 was performed on the MM cohort using the log-rank test (A) The telomere
16 dysfunction threshold (<3.81kb) identified a subset of MM patients with inferior
17 survival. (B) In keeping with previous reports, the ISS 3 sub-group also showed
18 significantly inferior survival compared to the combined ISS 1/2 sub-group. (C) Even
19 after adjustment for ISS and age, MM patients with telomere length <3.81kb had
20 significantly shorter survival. (D) The combination of ISS and the telomere
21 dysfunction threshold provided a refinement of their prognostic information. ISS 1/2
22 patients with short telomeres, or ISS 3 patients with long telomeres had
23 intermediate survival when compared to concordant groups consisting of ISS 1/2 and
24 long telomeres and ISS 3 and short telomeres.



Hyatt_Figure 2



1